<DOC>
	<DOCNO>NCT02304367</DOCNO>
	<brief_summary>UX023T-CL201 , open-label , Phase 2 study . The study conduct adult age 18 year old TIO ENS whose tumor/skin lesion inoperable ass efficacy safety KRN23 administer via subcutaneous injection monthly ( every 4 week ) total 144 week . Subjects need discontinue oral phosphate vitamin D metabolite therapy prior randomization throughout duration study .</brief_summary>
	<brief_title>Study KRN23 Adult Subjects With Tumor-Induced Osteomalacia ( TIO ) Epidermal Nevus Syndrome ( ENS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nevus</mesh_term>
	<mesh_term>Osteomalacia</mesh_term>
	<mesh_term>Neoplasms , Connective Tissue</mesh_term>
	<mesh_term>Nevus , Sebaceous Jadassohn</mesh_term>
	<criteria>1 . Have clinical diagnosis TIO/ENS base evidence excessive FGF23 amenable cure surgical excision offend tumor/lesion ( documented investigator ) 2 . Be ≥18 year age 3 . Have fast serum phosphorus level &lt; 2.5 mg/dL 4 . Have FGF23 level ≥ 100 pg/mL Kainos assay 5 . Have ratio renal tubular maximum reabsorption rate phosphate glomerular filtration rate ( TmP/GFR ) &lt; 2.5 mg/dL 6 . Have estimate glomerular filtration rate ( eGFR ) ≥60 mL/min ( use CockcroftGault formula ) . Subjects eGFR ≥30 &lt; 60 mL/min consider eligible long opinion investigator decline renal function relate nephrocalcinosis . 7 . Have correct serum calcium level &lt; 10.8 mg/dL 8 . Have negative pregnancy test Screening willing additional pregnancy test study ( female childbearing potential ) . Females consider childbearing potential include menopause least 2 year , tubal ligation least 1 year prior Screening , total hysterectomy 9 . Be willing use acceptable method contraception participate study ( sexually active subject ) , 12 week last dose study drug 10 . Be willing provide access prior medical record determine eligibility include imaging , biochemical , diagnostic , medical , surgical history data 11 . Provide write informed consent nature study explain , prior researchrelated procedure 12 . Be willing able complete aspect study , adhere study visit schedule comply assessment ( opinion investigator ) 1 . Have prior diagnosis human immunodeficiency virus ( HIV ) , hepatitis B and/or hepatitis C 2 . Have history recurrent infection , predisposition infection , know immunodeficiency 3 . Are pregnant breastfeed Screening plan become pregnant ( self partner ) time study 4 . Have participate investigational drug device trial within 30 day prior Screening currently enrol another study investigational product device 5 . Have use therapeutic monoclonal antibody , include KRN23 , within 90 day prior Screening history allergic anaphylactic reaction mAb 6 . Have history hypersensitivity KRN23 excipients , judgment investigator , place subject increase risk adverse effect 7 . Have use pharmacologic vitamin D metabolite analog ( e.g. , calcitriol , doxercalciferol , paricalcitol ) , phosphate , aluminum hydroxide antacid ( e.g. , Maalox® Mylanta® ) within 2 week prior Screening study 8 . Have use medication suppress PTH ( e.g. , Sensipar® , cinacalcet , calcimimetics ) within 2 month prior Screening 9 . Have history malignancy within 5 year study entry exception PMTMCT ( Phosphaturic mesenchymal tumor mixed connective tissue type ) tumor nonmelanoma skin cancer basal cell skin cancer 10 . Have donate blood blood product within 60 day prior Screening 11 . Have history allergic reaction show adverse reaction tetracycline ( e.g. , tetracycline HCl demeclocycline ) , benzodiazepine , fentanyl lidocaine 12 . Have condition , opinion investigator sponsor , could present concern either subject safety difficulty data interpretation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TIO</keyword>
	<keyword>ENS</keyword>
	<keyword>FGF23</keyword>
	<keyword>KRN23</keyword>
</DOC>